Study for subjects with NASH cirrhosis

UVA Tracking #
HSR200227
Principal Investigator
Stephen H Caldwell
Contact
Jaye Davis
Contact Email
Contact Phone
434.924.1784
Official Trial Title
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR-MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
Study Description

The hepatology department seeks adults over 18 with NASH cirrhosis for a research study. The purpose of the study is to determine if Belapectin is successful in preventing esophageal varices from forming in subjects with cirrhosis and portal hypertension.

You may be eligible for this study if you have NASH cirrhosis and portal hypertension, but do not already have esophageal varices or other signs of decompensation related to cirrhosis.

Study involves having an EGD to determine if you have portal hypertension and varices, then coming to UVA every other week for up to 36 months for an infusion and study visit that will last up to 3 hours. Also during your time in the study you will have 2 other EGDs and have imaging (CT or MRI) along with ultrasounds to ensure that you are not forming any varices.

Study-related insert exams, tests and experimental medication provided free of charge.

Compensation

$75 per visit